Home > Healthcare > Pharmaceuticals > Finished Drug Form > Lipid Regulators Market
Lipid Regulators Market was valued at USD 32.4 billion in 2023 and is set to register a CAGR of 3.8% from 2024 – 2032. The lipid regulators industry is experiencing growth driven by factors such as the rising prevalence of dyslipidemia and cardiovascular disease, advancements in drug development, increased prescription rate, and growing awareness of the importance of lipid management in reducing cardiovascular risk. Also, with the growing ageing population and increasing focus on preventive healthcare, the market is expected witness lucrative growth over the coming years.
For instance, according to World Population Prospects 2022, the population aged 65 years and above is expected to rise from 10% in 2022 to 16% in 2050. As the population ages, the risk of developing dyslipidemia and cardiovascular disease also increases, thereby driving the growth of the market.
Lipid regulators, also known as lipid-lowering agents or lipid-lowering drugs, are medications used to manage abnormal levels of lipids (fats) in the blood, primarily cholesterol and triglycerides. Elevated levels of these lipids are associated with an increased risk of cardiovascular diseases such as heart attacks and strokes. Lipid regulators can help lower cholesterol and triglyceride levels, reducing the risk of these diseases.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Lipid Regulators Market Size in 2023: | USD 32.4 Billion |
Forecast Period: | 2024 to 2032 |
Forecast Period 2024 to 2032 CAGR: | 3.8% |
2032 Value Projection: | USD 44.9 Billion |
Historical Data for: | 2018 – 2023 |
No. of Pages: | 203 |
Tables, Charts & Figures: | 355 |
Segments covered: | Type, Indication, Route of Administration, Distribution Channel, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|